New FDA Guidance on T2D Trial Design Provides Flexibility New FDA Guidance on T2D Trial Design Provides Flexibility

The FDA released new draft guidance for the evaluation of type 2 diabetes drugs. Dr John Buse discusses the impact this could have on clinical trials and the medications we might see from the changes.Medscape Diabetes & Endocrinology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news